JP2003507412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003507412A5 JP2003507412A5 JP2001518031A JP2001518031A JP2003507412A5 JP 2003507412 A5 JP2003507412 A5 JP 2003507412A5 JP 2001518031 A JP2001518031 A JP 2001518031A JP 2001518031 A JP2001518031 A JP 2001518031A JP 2003507412 A5 JP2003507412 A5 JP 2003507412A5
- Authority
- JP
- Japan
- Prior art keywords
- particle
- microns
- particles
- amino acid
- phospholipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 description 37
- 229940024606 amino acid Drugs 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 150000003904 phospholipids Chemical class 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 230000002209 hydrophobic effect Effects 0.000 description 10
- 229940039227 diagnostic agent Drugs 0.000 description 8
- 239000000032 diagnostic agent Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000000069 prophylactic effect Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 150000008105 phosphatidylcholines Chemical class 0.000 description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 4
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 4
- 229940067626 phosphatidylinositols Drugs 0.000 description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 description 4
- 150000008106 phosphatidylserines Chemical class 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- -1 phosphatidyl glycerols Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/382,959 US6586008B1 (en) | 1999-08-25 | 1999-08-25 | Use of simple amino acids to form porous particles during spray drying |
| US09/382,959 | 1999-08-25 | ||
| PCT/US2000/023149 WO2001013893A2 (en) | 1999-08-25 | 2000-08-23 | Use of simple amino acids to form porous particles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003507412A JP2003507412A (ja) | 2003-02-25 |
| JP2003507412A5 true JP2003507412A5 (enExample) | 2007-06-28 |
Family
ID=23511119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001518031A Pending JP2003507412A (ja) | 1999-08-25 | 2000-08-23 | 多孔性粒子を形成するための単純アミノ酸の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US6586008B1 (enExample) |
| EP (2) | EP1637128A3 (enExample) |
| JP (1) | JP2003507412A (enExample) |
| AT (1) | ATE319429T1 (enExample) |
| AU (1) | AU764738B2 (enExample) |
| CA (1) | CA2382651C (enExample) |
| DE (1) | DE60026544T2 (enExample) |
| DK (1) | DK1210068T3 (enExample) |
| ES (1) | ES2258981T3 (enExample) |
| PT (1) | PT1210068E (enExample) |
| WO (1) | WO2001013893A2 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020052310A1 (en) * | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
| US6458338B1 (en) * | 1998-09-22 | 2002-10-01 | Aeropharm Technology Incorporated | Amino acid stabilized medicinal aerosol formulations |
| US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| US6749835B1 (en) * | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
| US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US20020150626A1 (en) * | 2000-10-16 | 2002-10-17 | Kohane Daniel S. | Lipid-protein-sugar particles for delivery of nucleic acids |
| PL365736A1 (en) * | 2001-02-06 | 2005-01-10 | Innovata Biomed Limited | Bimodal dry powder formulation for inhalation |
| US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
| US20050123509A1 (en) * | 2001-10-19 | 2005-06-09 | Lehrman S. R. | Modulating charge density to produce improvements in the characteristics of spray-dried proteins |
| US20050013867A1 (en) * | 2001-10-19 | 2005-01-20 | Lehrman S. Russ | Use of proton sequestering agents in drug formulations |
| AU2002346424A1 (en) * | 2001-11-19 | 2003-06-10 | Becton, Dickinson And Company | Pharmaceutical compositions in particulate form |
| JP2005511629A (ja) * | 2001-11-20 | 2005-04-28 | アドバンスト インハレーション リサーチ，インコーポレイテッド | 持続作用生成物送達用組成物 |
| WO2003053411A1 (en) * | 2001-12-19 | 2003-07-03 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
| KR20040093155A (ko) * | 2002-03-18 | 2004-11-04 | 야마노우치세이야쿠 가부시키가이샤 | 흡입용 분말 의약조성물 및 이의 제조방법 |
| US7754242B2 (en) * | 2002-03-20 | 2010-07-13 | Alkermes, Inc. | Inhalable sustained therapeutic formulations |
| US20110123574A1 (en) * | 2002-03-20 | 2011-05-26 | Alkermes, Inc. | Inhalable sustained therapeutic formulations |
| ES2718455T3 (es) | 2002-03-20 | 2019-07-02 | Civitas Therapeutics Inc | Formulaciones terapéuticas sostenidas inhalables |
| US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
| WO2004093848A2 (en) * | 2003-04-14 | 2004-11-04 | Vectura Ltd | Dry power inhaler devices and dry power formulations for enhancing dosing efficiency |
| KR20120080243A (ko) * | 2003-05-28 | 2012-07-16 | 노바르티스 아게 | 아미노산 및/또는 인지질로 부분 또는 완전 코팅된 수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의 분무 건조법 |
| WO2005025535A2 (en) * | 2003-09-15 | 2005-03-24 | Vectura Limited | Methods for preparing pharmaceutical compositions |
| CA2554973A1 (en) * | 2004-02-10 | 2005-08-25 | Advanced Inhalation Research, Inc. | Particles for inhalation rapid release properties |
| US7611709B2 (en) | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
| US7723306B2 (en) | 2004-05-10 | 2010-05-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation |
| SG153833A1 (en) | 2004-06-18 | 2009-07-29 | Novartis Vaccines & Diagnostic | Methods of treatment of endobronchial infections |
| WO2006014930A2 (en) * | 2004-07-26 | 2006-02-09 | Cotherix, Inc. | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
| BRPI0517374A (pt) * | 2004-10-29 | 2008-10-07 | Harvard College | formulação para tratamento ou prevenção de infecção respiratória, método para tratamento |
| US20060105051A1 (en) * | 2004-11-18 | 2006-05-18 | Blair Jackson | Manufacture of particles for pulmonary drug delivery by carbon dioxide assisted nebulization |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| US20060134009A1 (en) * | 2004-12-16 | 2006-06-22 | Daniel Deaver | Low dose corticosteroid powders for inhalation |
| RS55114B1 (sr) | 2005-05-18 | 2016-12-30 | Raptor Pharmaceuticals Inc | Aerosolizovani fluorohinoloni i njihove upotrebe |
| US8524735B2 (en) | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| GB0524194D0 (en) * | 2005-11-28 | 2006-01-04 | Univ Aston | Respirable powders |
| ES2473665T3 (es) * | 2005-11-28 | 2014-07-07 | Verrow Pharmaceuticals, Inc. | Composiciones útiles para reducir la nefrotoxicidad y los métodos de uso de las mismas |
| US20070219127A1 (en) * | 2006-03-20 | 2007-09-20 | Walt John G | Cyclosporin a compositions |
| DE102006030164A1 (de) * | 2006-06-29 | 2008-01-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Pulver |
| WO2008130220A1 (en) * | 2007-04-20 | 2008-10-30 | N.V. Nutricia | Process for dispersing amino acids |
| NO2344129T3 (enExample) | 2008-10-07 | 2018-07-21 | ||
| PT2346509T (pt) | 2008-10-07 | 2020-08-05 | Horizon Orphan Llc | Inalação de levofloxacina para redução da inflamação pulmonar |
| GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
| EP2435025B1 (en) * | 2009-05-29 | 2016-07-06 | Pearl Therapeutics, Inc. | Respiratory delivery of active agents |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| BR112012004692B8 (pt) | 2009-09-04 | 2021-05-25 | Mpex Pharmaceuticals Inc | solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano |
| WO2012106382A1 (en) | 2011-01-31 | 2012-08-09 | Genoa Pharmaceuticals, Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US9572774B2 (en) | 2011-05-19 | 2017-02-21 | Savara Inc. | Dry powder vancomycin compositions and associated methods |
| AU2012254999B2 (en) * | 2011-05-19 | 2016-02-11 | Savara, Inc. | Dry powder vancomycin compositions and associated methods |
| CN102225058A (zh) * | 2011-06-22 | 2011-10-26 | 中国药科大学 | 磷酸奥司他韦吸入粉雾剂及其制备方法 |
| WO2014074797A1 (en) | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
| AU2014212109B2 (en) | 2013-02-01 | 2018-05-31 | Glialogix, Inc. | Compositions and methods for the treatment of neurodegenerative and other diseases |
| JP6454323B2 (ja) | 2013-03-15 | 2019-01-16 | パール セラピューティクス，インコーポレイテッド | 粒子状結晶性材料のコンディショニングのための方法及びシステム |
| AU2014296032A1 (en) | 2013-07-31 | 2016-03-17 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| NZ722927A (en) | 2014-01-10 | 2022-07-29 | Avalyn Pharma Inc | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| DK3104853T3 (da) | 2014-02-10 | 2019-12-09 | Respivant Sciences Gmbh | Behandling med mastcellestabilisatorer til systemiske forstyrrelser |
| WO2015120392A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Mast cell stabilizers for lung disease treatment |
| EP3174893B1 (en) * | 2014-07-30 | 2020-05-06 | Genome Protection, Inc. | Flagellin compositions and uses |
| GB201415381D0 (en) * | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
| DK3212212T3 (da) | 2014-10-31 | 2020-12-21 | Univ Monash | Pulverformulering |
| MA40910A (fr) | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| US9585835B1 (en) * | 2015-09-16 | 2017-03-07 | Sansa Corporation (Barbados) Inc. | Inhalable nicotine formulations and methods of making and using the same |
| JP6953414B2 (ja) * | 2016-01-20 | 2021-10-27 | フラリー パウダーズ エルエルシーＦｌｕｒｒｙ Ｐｏｗｄｅｒｓ，Ｌｌｃ | 親油性成分を含む吸入に好適な分散性の噴霧乾燥粉末を製造する方法 |
| US11833118B2 (en) | 2016-01-20 | 2023-12-05 | Flurry Powders, Llc | Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation |
| MA45451A (fr) * | 2016-06-24 | 2019-05-01 | Civitas Therapeutics Inc | Formulations tensioactives destinées à l'inhalation |
| WO2018002779A1 (en) * | 2016-06-30 | 2018-01-04 | Philip Morris Products S.A. | Nicotine particles |
| US20190133940A1 (en) * | 2016-06-30 | 2019-05-09 | Philip Morris Products S.A. | Nicotine particles and compositions |
| AU2017321495A1 (en) | 2016-08-31 | 2019-03-21 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
| JP2019531308A (ja) | 2016-10-07 | 2019-10-31 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | 肺線維症の治療のためのクロモリン組成物 |
| US20180110760A1 (en) | 2016-10-21 | 2018-04-26 | Glialogix, Inc. | Compositions and methods for the treatmentof neurodegenerative and other diseases |
| CA3048677A1 (en) * | 2017-03-07 | 2018-09-13 | Philip Morris Products S.A. | Inhalable nicotine formulations, and methods of making and using thereof |
| GB2577420B (en) | 2017-05-22 | 2022-07-06 | Insmed Inc | Glycopeptide derivative compounds and uses thereof |
| EP3727418A4 (en) * | 2017-12-21 | 2021-10-27 | Civitas Therapeutics, Inc. | SURFACTANT FORMULATIONS FOR INHALATION |
| EP3727353A4 (en) * | 2017-12-21 | 2021-10-13 | Civitas Therapeutics, Inc. | SURFACTANT FORMULATIONS FOR INHALATION |
| CN112703000B (zh) | 2018-07-23 | 2024-05-31 | 特雷维治疗股份有限公司 | 慢性咳嗽、呼吸急促和呼吸困难的治疗 |
| AU2021206252A1 (en) | 2020-01-10 | 2022-07-28 | Trevi Therapeutics, Inc. | Methods of administering nalbuphine |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| DK0679088T3 (da) | 1992-09-29 | 2002-10-28 | Inhale Therapeutic Syst | Pulmonal levering af aktive fragmenter af parathyreoideaea hormon |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| CA2183577C (en) | 1994-03-07 | 2007-10-30 | John S. Patton | Methods and compositions for pulmonary delivery of insulin |
| ATE299892T1 (de) | 1994-05-18 | 2005-08-15 | Nektar Therapeutics | Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen |
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| ES2237767T3 (es) | 1995-04-14 | 2005-08-01 | Nektar Therapeutics | Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada. |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| GB9515182D0 (en) | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| JP4233608B2 (ja) * | 1996-10-15 | 2009-03-04 | 塩野義製薬株式会社 | 自己抗体測定方法 |
| ATE287257T1 (de) | 1997-01-16 | 2005-02-15 | Massachusetts Inst Technology | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| AU750567B2 (en) | 1997-09-29 | 2002-07-25 | Novartis Ag | Stabilized preparations for use in nebulizers |
| GB9827145D0 (en) | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
-
1999
- 1999-08-25 US US09/382,959 patent/US6586008B1/en not_active Expired - Lifetime
-
2000
- 2000-08-23 AT AT00957716T patent/ATE319429T1/de active
- 2000-08-23 AU AU69296/00A patent/AU764738B2/en not_active Ceased
- 2000-08-23 JP JP2001518031A patent/JP2003507412A/ja active Pending
- 2000-08-23 DK DK00957716T patent/DK1210068T3/da active
- 2000-08-23 EP EP05077639A patent/EP1637128A3/en not_active Withdrawn
- 2000-08-23 ES ES00957716T patent/ES2258981T3/es not_active Expired - Lifetime
- 2000-08-23 WO PCT/US2000/023149 patent/WO2001013893A2/en not_active Ceased
- 2000-08-23 PT PT00957716T patent/PT1210068E/pt unknown
- 2000-08-23 CA CA002382651A patent/CA2382651C/en not_active Expired - Lifetime
- 2000-08-23 DE DE60026544T patent/DE60026544T2/de not_active Expired - Lifetime
- 2000-08-23 EP EP00957716A patent/EP1210068B1/en not_active Expired - Lifetime
-
2006
- 2006-12-12 US US11/637,353 patent/US20070104658A1/en not_active Abandoned
-
2007
- 2007-10-17 US US11/873,467 patent/US20080160092A1/en not_active Abandoned
- 2007-10-17 US US11/873,472 patent/US20080160098A1/en not_active Abandoned
-
2011
- 2011-01-20 US US13/010,032 patent/US8268358B2/en not_active Expired - Fee Related
-
2012
- 2012-08-17 US US13/588,549 patent/US9333174B2/en not_active Expired - Fee Related
-
2016
- 2016-04-07 US US15/092,799 patent/US20160287517A1/en not_active Abandoned
-
2017
- 2017-01-26 US US15/416,328 patent/US20170354602A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003507412A5 (enExample) | ||
| CA2382651A1 (en) | Use of simple amino acids to form porous particles | |
| JP2003507411A5 (enExample) | ||
| AU693632B2 (en) | Proliposome powders for inhalation | |
| RU2202340C2 (ru) | Система доставки лекарства | |
| JP4526702B2 (ja) | 安定化生物活性処方物およびその使用方法 | |
| AU2007297691B2 (en) | Pulmonary surfactant formulations and methods for promoting mucus clearance | |
| JP2004520409A (ja) | 乾燥粉体製剤からの放出の調節 | |
| KR20050095838A (ko) | 폐 투여용 불용성 활성제를 갖는 약제학적 제형물 | |
| JPH11506790A (ja) | 肺疾患の治療に有用なジヌクレオチド | |
| CA2277801A1 (en) | Preparation of particles for inhalation | |
| CA2336139A1 (en) | Large porous particles emitted from an inhaler | |
| JP2013532705A (ja) | ホスホジエステラーゼ阻害剤を含む乾燥粉末製剤 | |
| WO2000042993A2 (en) | Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery | |
| JP2774379B2 (ja) | 医薬エアロゾール組成物ならびにそれらのウイルス疾患の治療および予防用途 | |
| WO2009143011A1 (en) | Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions | |
| JP2007513180A (ja) | 喘息の処置および予防 | |
| JP2002532405A (ja) | オピオイド吸入製剤 | |
| WO2004054556A1 (en) | Pharmaceutical porous particles | |
| JP2017523189A (ja) | 吸入用の乾燥粉末製剤 | |
| JPS63502899A (ja) | リポソームおよびβ↓２‐レセプター活性物質の組成物 | |
| WO2022235621A1 (en) | Methods for treating a pulmonary disease with an alk-5 (tgf beta r1) inhibitor | |
| JPH10512876A (ja) | コルチコステロイドを含有するリポソーム | |
| WO2025264889A1 (en) | Nebulizer kits and uses thereof | |
| KR102259824B1 (ko) | 보센탄을 함유한 약학 제제 |